AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Norikazu Masuda'
:
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
Publication Year: 2017
DOI: https://doi.org/10.18632/oncotarget.22110
Abstract:
Add to Library
Authors:
Rin Ogiya
Naoki Niikura
Nobue Kumaki
Hiroyuki Yasojima
Tsutomu Iwasa
Chizuko Kanbayashi
Risa Oshitanai
Michiko Tsuneizumi
Kenichi Watanabe
Akira Matsui
Tomomi Fujisawa
Shigehira Saji
Norikazu Masuda
Yutaka Tokuda
Hiroji Iwata
Abstract PD1-03: A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-pd1-03
Abstract:
Add to Library
Authors:
Yukinori Ozaki
Toru Mukohara
Junji Tsurutani
Masato Takahashi
Koji Matsumoto
Manabu Futamura
Norikazu Masuda
Shigehisa Kitano
Kenichi Yoshimura
Hironobu Minami
Toshimi Takano
Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-gs3-01
Abstract:
Add to Library
Authors:
Hope S. Rugo
Thomas Powles
David W. Cescon
Zbigniew Nowecki
Seock‐Ah Im
Mastura Md Yusof
Luis de la Cruz‐Merino
Oleg Lipatov
Carlos H. Barrios
José Manuel Pérez-García
Hiroji Iwata
Norikazu Masuda
Marco Torregroza Otero
Erhan Gökmen
Sherene Loi
Zifang Guo
Jing Zhao
Vassiliki Karantza
Gursel Aktan
Javier Cortés
Abstract PS12-10: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps12-10
Abstract:
Add to Library
Authors:
Jun Masuda
Junji Tsurutani
Norikazu Masuda
Yuko Tanabe
Tsutomu Iwasa
Masato Takahashi
Manabu Futamura
Koji Matsumoto
Kenjiro Aogi
Hiroji Iwata
Mari Hosonaga
Toru Mukohara
Kenichi Yoshimura
Toshimi Takano
Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial)
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-ot2-04-07
Abstract:
Add to Library
Authors:
Jun Masuda
Junji Tsurutani
Norikazu Masuda
Manabu Futamura
Koji Matsumoto
Kenjiro Aogi
Masato Takahashi
Hiroji Iwata
Tsutomu Iwasa
Toru Mukohara
Kenichi Yoshimura
Takayuki Ueno
Toshimi Takano
Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs1-02
Abstract:
Add to Library
Authors:
Javier Cortés
David W. Cescon
Hope S. Rugo
Zbigniew Nowecki
Seock‐Ah Im
Mastura Md Yusof
Carlos Gallardo
Oleg Lipatov
Carlos H. Barrios
José Manuel Pérez-García
Hiroji Iwata
Norikazu Masuda
Marco Torregroza Otero
Erhan Gökmen
Sherene Loi
Zifang Guo
Xuan Zhou
Vassiliki Karantza
Wilbur Pan
Thomas Powles
Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-pd4-03
Abstract:
Add to Library
Authors:
Mark E. Robson
Seock‐Ah Im
Elżbieta Senkus
Binghe Xu
Susan M. Domchek
Norikazu Masuda
Suzette Delaloge
Wěi Li
Nadine Tung
Anne Armstrong
Wendy Bannister
Carsten Goessl
A. Allen
Pierfranco Conté
Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-pd1-09
Abstract:
Add to Library
Authors:
Ian E. Krop
Kan Yonemori
Shunji Takahashi
Kenichi Inoue
Takahiro Nakayama
Hiroji Iwata
Tatsuya Toyama
Yutaka Yamamoto
Masato Takahashi
Akihiko Osaki
Shigehira Saji
Yasuaki Sagara
Joyce O’Shaughnessy
Tiffany A. Traina
Shoichi Ohwada
Zhenhao Qi
Yang Qiu
Hiroshi Onuma
O. P. Sharma
Sabeen Mekan
Norikazu Masuda
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Publication Year: 2017
DOI: https://doi.org/10.1016/j.ejca.2016.09.024
Abstract:
Add to Library
Authors:
David Miles
David Cameron
Igor Bondarenko
Lyudmila Manzyuk
Juan Carlos Alcedo
R.I. Lopez
Seock‐Ah Im
Jean Luc Canon
Yaroslav Shparyk
Denise A. Yardley
Norikazu Masuda
Jungsil Ro
Neelima Denduluri
Stanislas Hubeaux
Cheng S. Quah
Carlos Bais
Joyce O’Shaughnessy
Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ot-28-01
Abstract:
Add to Library
Authors:
Sara A. Hurvitz
Linda T. Vahdat
Nadia Harbeck
Antonio C. Wolff
Sara M. Tolaney
Sherene Loi
Norikazu Masuda
Joyce O’Shaughnessy
Cassie Dong
Luke Walker
Evelyn Rustia
Virginia F. Borges
Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd13-11
Abstract:
Add to Library
Authors:
Antonio Llombart‐Cussac
George W. Sledge
Masakazu Toi
Patrick Neven
Joohyuk Sohn
Kenichi Inoue
Xavier Pivot
Meena Okera
Norikazu Masuda
Peter A. Kaufman
Han Koh
Eva‐Maria Grischke
Pierfranco Conté
Valérie André
Yuanyuan Bian
Ashwin Shahir
Gertjan van Hal
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Publication Year: 2016
DOI: https://doi.org/10.1016/j.ejca.2016.09.024
Abstract:
Add to Library
Authors:
David Miles
David Cameron
Igor Bondarenko
Lyudmila Manzyuk
Juan Carlos Alcedo
R.I. Lopez
Seock‐Ah Im
Jean‐Luc Canon
Yaroslav Shparyk
Denise A. Yardley
Norikazu Masuda
Jungsil Ro
Neelima Denduluri
Stanislas Hubeaux
Cheng S. Quah
Carlos Bais
Joyce O’Shaughnessy
Bladder Carcinoma Producing Granulocyte Colony-Stimulating Factor: A Case Report
Publication Year: 1993
DOI: https://doi.org/10.1016/s0022-5347(17)36229-8
Abstract:
Add to Library
Authors:
Hidesuke Satoh
Yoshiyuki Abe
Yûkô Fukui
Yukikuni Komine
Masato Nakamura
Norikazu Tamaoki
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition
Publication Year: 2011
DOI: https://doi.org/10.1111/j.1349-7006.2011.01867.x
Abstract:
Add to Library
Authors:
Masakazu Toi
Shigehira Saji
Norikazu Masuda
Katsumasa Kuroi
Nobuaki Sato
Hiroyuki Takei
Yutaka Yamamoto
Shinji Ohno
Hiroko Yamashita
K Hisamatsu
Kenjiro Aogi
Hiroji Iwata
Masahiro Takada
Takayuki Ueno
Shigetoyo Saji
Niramol Chanplakorn
Takashi Suzuki
Hironobu Sasano
Abstract CT038: OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline <i>BRCA</i> mutation (g<i>BRCA</i>m)
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct038
Abstract:
Add to Library
Authors:
Mark E. Robson
Seock‐Ah Im
Elżbieta Senkus
Binghe Xu
Susan M. Domchek
Norikazu Masuda
Suzette Delaloge
Wěi Li
Nadine Tung
Anne Armstrong
Wenting Wu
Carsten Goessl
Sarah Runswick
Pierfranco Conté
Found 93 results in 0.07 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"